dual gip/glp-1 receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Tirzepatide, a dual GIP/GLP-1 receptor
Description
Diabetes Care 44(3):765773 Kim WJ, Lee SJ, Lee E, Lee EY, Han K (2022) Risk of incident dementia according to glycemic status and comorbidities of hyperglycemia: a nationwide population-based cohort study
By 2017 revenue from liraglutide was US $843 million, and the overall market for GLP-1 drugs was growing 30 percent, up from just 3 percent in 2014 (Staton)
It is a clinical one
GLP-1RAs such as semaglutide have proven efficacy in HFpEF and are being studied in people with PD as well as in trials for Alzheimers disease
Mounjaro works similarly to the other drugs in the GLP-1 receptor agonist family, but it has additional effects that appears to give it a slight edge
